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had a discharge diagnosis of GIB based on the International Classification of Diseases-9 (ICD-9) code 578.x between April 1, 2008, and October 31, 2011. This was cross-referenced with a database of all blood product transfusions during the same time. The list of matching patients was screened for admissions to the ICU, either directly from the emergency room/outside facility or through inpatient transfers from medicine floors. The records of patients who met these criteria were then analyzed for data regarding demographics, blood product administration (timing and product type), duration of admission to the ICU and hospital, and risk of death during the first 28 days, Model for End-Sage Liver Disease (MELD) score, and Acute Physiologic Chronic Health Evaluation (APACHE) II score. We also obtained data regarding diagnostic testing to identify the location and etiology of the GIB.
The standard practices at our institution are to admit or transfer patients with active GIB to the medical ICU service, use leukoreduced red blood cells (RBCs) and apheresed platelets (PLT) equivalent to 6 units of nondonor-matched PLT. We also have a 95% male-only FFP policy with only Rh type AB plasma having the possibility of female donors. To standardize data, vital signs and laboratory values on ICU admission were used for data analysis except in situations where the most abnormal value was preferred (e.g., APACHE II calculations). Our institution uses a standard transfusion threshold of hemoglobin <7 g/dL for transfusion except in cases of hemodynamic instability and transfusion of 10 or more units of RBC within a 24-h period in a 1 unit RBC: 1 unit FFP: 1 unit PLT ratio as MT.
Outcomes
MT was defined as transfusion of 10 or more units of RBC within a 24-h period in a 1 unit RBC: 1 unit FFP: 1 unit PLT ratio. [11] [12] [13] ICU vital signs were monitored for worsening Alveolar-arterial gradient with an increase in the fraction of inspired oxygen (FiO 2 ) needed to maintain an oxygen saturation (SpO 2 ) ≥92% and PaO 2 ≥55 mmHg.
TRALI has been previously defined as development of new acute lung injury (ALI) with onset of signs and symptoms within 6 h of transfusion with new bilateral pulmonary infiltrates, absence of circulatory overload, or preexisting ALI before transfusion with no other ALI risk factors such as pneumonia or aspiration. [2, 3] A PaO 2 /FiO 2 ratio ≤300 was used as the definition of ALI. [14] If no arterial blood gas sampling was performed, change in saturation to FiO 2 (SF ratio) from before transfusion was used. [15] [16] [17] [18] [19] All cases of ALI were assessed for other causes of lung injury including sepsis, pneumonia, aspiration, or severe pancreatitis which had to be ruled out to qualify for a TRALI designation. Review of radiology films along with the official radiology interpretation was used for determination of bilateral infiltrates. Two authors (JC, MD) reviewed all cases with adjudication by the senior author (AK) in case of issues.
Microbiology results were reviewed for infection defined as a sputum culture with a known bacterial pathogen, urinary culture with >100,000 colony-forming units of a known pathogen, or a blood culture positive for a bacterial or fungal pathogen. For patients with prolonged hospital admissions who may have required frequent transfusions (bone marrow transplant patients, hematologic malignancy, severe myelodysplastic syndrome, etc.), only transfusion data during the ICU admission were used in the analysis. MELD and APACHE II scores were calculated using the published guidelines. [20, 21] We used 28-day ICU-free days to avoid the confounding effect of death during hospitalization. [22] ICU-free days in a 28-day period were determined by subtracting the ICU length of stay (LOS) from 28. [22, 23] The 28-day ICU-free days were considered to be zero if a patient died before ICU discharge or stayed in the ICU for longer than 28 days.
Statistical analysis
Baseline demographic and clinical characteristics of patients stratified by massive versus non-MT are summarized in Table 1 with categorical variables presented as counts or frequencies and continuous data summarized by median and interquartile range (IQR). For each characteristic, a Wilcoxon rank-sum test or Chi-square test was carried out to determine statistical differences.
To identify the demographic and clinical characteristics associated with TRALI and risk of death, a step-wise regression procedure was used. A significance level of 0.05 was used as the cutoff for adding variables to the model, and a level of 0.20 was used as the cutoff for removing variables. For model development, based on significance on univariate analysis, APACHE II score, MELD score, mean arterial pressure (MAP), hematocrit, and respiratory rate were locked in the model for TRALI. APACHE II score, MELD score, and TRALI were locked in the model for death. All analyses were carried out in Stata IC version 13.1 (StataCorp LP, College Station, TX, USA).
results
During the 43 months between April 1, 2008, and October 31, 2011, 1168 patients had a discharge diagnosis of GIB and 214 (18.3%) received at least one transfusion. 169 (79%) of these patients were admitted to the ICU and were included in the final data analysis. During the same period, there were 2154 admissions to the ICU, of whom 1544 (71.7%) were discharged from the hospital while 610 (28.3%) died during the hospital admission [ Figure 1 ]. There were 901 (41.8%) females and 1253 (58.2%) males. The average age of the patients admitted to the ICU was 54.0 ± 16.5 years. Average LOS in the ICU was 11.0 ± 14.1 days. The mean number of ICU-free days was 13.4 ± 11.8. The 169 patients with GIB constituted 7.9% of ICU admissions.
The median age of patients with GIB was 61 years, (IQR: 51-69), the composition of this population was 42% of females and 58% of males, the median LOS in the hospital was 6 days (IQR: [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] , and the median LOS in the ICU was 3 days (IQR: [2] [3] [4] [5] [6] . Nearly 66.3% of patients were alive and discharged from the hospital while 33.7% died during the hospital stay. The median number of RBC units transfused in the first 24 h was 2 units [IQR: 2-4, Figure 2] , and the median number of RBC units transfused in the entire stay was 4 units [IQR: 2-8, Figure 3 ]. In the MT group, three patients received 2 units and one patient received 1-unit RBC before transfer to our facility.
The MT protocol was used in 13 (7.7%) patients with GIB. Eight patients had bleeding caused by a source proximal to the pylorus based on clinical findings of hematemesis (one patient with bleeding after percutaneous endoscopic gastrostomy placement), one had bleeding from a colon rupture, and the source of bleeding could not be identified in four patients due to hemodynamic instability precluding Table 1 ]. Six (46.2%) of the 13 patients who received MT developed TRALI, by contrast 4 (2.6%) of the 156 patients who did not require MT developed TRALI. Development of TRALI increased OR for death for 2.3 times (95% CI: 1.1-4.6, P = 0.02). Infections developed in 16 (9.5%) patients, only 1 of whom required MT. The median ICU LOS was 5 days (IQR: 2-6) for patients who received MT and 3 days (IQR: 2-6) for those who did not receive MT (P = 0.86). Patients who received MT had no ICU-free days in a 28-day period, while the contrasting population had 20 ICU-free days (IQR: 0-25, P = 0.0003). The number of units transfused in the first 24 h as well as total units transfused for the admission was higher in the TRALI group [ further diagnostic testing. The diagnostic testing and source of bleeding for patients receiving MT are listed in Table 2 . death at 5.06 (95% CI: 1.32-23.37, P = 0.0048) for those who received MT. In scenarios where the site of bleeding could not be identified, it was more likely that MT was used as a treatment. Of the 13 patients without a known source of bleeding, 6 (46.2) required activation of the MT protocol. TRALI did not increase the duration of ICU stay or the total hospital stay but was associated with reduced ICU-free days [ Table 3 ].
In a step-wise regression procedure with forward selection, after adjusting for age, sex, body mass index (BMI), baseline vitals, and laboratory data, MT was associated with an increased risk of TRALI with OR 17.9 [95% CI: 2.9-111.2, P = 0.002, Table 4 ]. After adjusting for age and sex, death was predicted by the APACHE II score with an increase in OR 1.17 per unit increase in APACHE II score (95% CI: 1.09-1.26 P < 0.001); baseline hematocrit, OR 1.0 (95% CI: 1.01-1.18, P = 0.027); admission respiratory rate, OR 1.06 (95% CI: 1.01-1.11, P = 0.023); and BMI, OR 1.11 (95% CI: 1.04-1.17, P = 0.001), but not by the use of MT protocol or development of TRALI [ Table 5 ]. [24] Data on the incidence of TRALI while using MT in medical patients with GIB are limited. [5, 25] We performed a retrospective analysis of patients who received transfusions for GIB to determine the association between TRALI and use of MT [ Tables 1 and 3] . After adjusting for age, sex, and BMI, MT use was associated with an increased risk of developing TRALI while the baseline APACHE II and MELD scores were not suggesting that TRALI was associated with the number of units transfused rather than the underlying severity of illness or presence of liver disease [ Table 4 ]. Odds of death were increased with TRALI on univariate analysis, but after adjusting for age and sex, death was predicted by APACHE II score, admission hematocrit, admission respiratory rate, and BMI [ Table 5 ].
Contrary to other studies, after adjusting for age and sex, our study did not show an increase in the incidence of death with increasing MELD score. [20, 26, 27] These differences may be explained either by our patients being transfused in a 1:1:1.8 ratio of RBC: FFP: PLT, thereby correcting coagulation abnormalities which may have mitigated the effects of abnormal liver function, or by the low incidence of severe liver disease in our patients.
The ratios of blood products transfused in the MT group in our study of 1:1:1.8 was consistent with the current MT guidelines of 1:1:1 as an approximation of whole blood. This is similar to the Pragmatic, Randomized Optimal Platelets and Plasma Ratios study which compared 1:1:1-1:1:2 transfusion ratios in trauma patients and showed that early administration of plasma, PLT, and RBCs in a 1:1:1 ratio compared with a 1:1:2 ratio did not result in significant differences in the risk of death within the first 24 h or at 30 days. [28] Our cohort had an increased risk of developing TRALI with the use of all blood products including FFP. Studies have noted the associations of FFP administration, especially female FFP, with TRALI. [25] Our institution uses male plasma for 95% of all FFP units other than AB blood type to decrease this likelihood. Our sample size was too small to assess for a dose-dependent association of blood products with TRALI due to the increased possibility of type II error.
Our study showed a slight increase in the risk of death with increasing BMI. Data describing the effects of BMI on ICU mortality are conflicting, but the general trend shows an inverse relationship between BMI and mortality. [29] [30] [31] [32] [33] Often, a higher BMI is protective against mortality, [33] but we did not find that in our study.
After adjusting for age, sex, and BMI, we were not able to identify any clinical parameters that could predict the need for utilization of a MT protocol. We noted that the use of MT was more likely when the site of bleeding could not be identified. This may be due to the fact that hemodynamically unstable patients are often incapable of enduring diagnostic procedures to help identify the exact source of bleeding.
The retrospective nature of our study makes it difficult to differentiate between TRALI, acute respiratory distress syndrome (ARDS) or transfusion-associated cardiac overload (TACO). We took all possible measures to exclude patients with ARDS and TACO from our TRALI group. We used the expert panel criteria for adjudication of acute posttransfusion hypoxemia with bilateral pulmonary infiltrates to differentiate between TRALI, TACO, ARDS/ALI, or other etiologies such as pneumonia, aspiration, congestive heart failure, or diffuse pulmonary hemorrhage by chart review. Initial screening was done by two authors followed by adjudication by the senior author to minimize the risk of inaccuracy. [3, 14] The hypovolemic nature of patients receiving MT for GI bleeding from hemorrhagic shock also reduces the chances of patients developing volume overload. [34] As our study is retrospective, we were unable to establish a causal link between MT and the development of TRALI. Prospective studies are needed to clarify this association. Based on ICD-9 data, we identified that it is possible that some patients with GIB may have been missed due to incorrect coding. Finally, these data represent information from only a single, academic tertiary center ICU and may not be suitable for extrapolation to all practice environments.
Despite these limitations, our study is one of the few assessing the role of MT in medical patients with GI bleeding and provides useful insight into risk factors for TRALI and the risk of death in this population.
conclusIon
In this retrospective analysis, we found that GIB constituted 7.9% of medical ICU admissions. A small percentage of these patients (7.7%) required activation of MT. The incidence of TRALI increased with the activation of MT as part of the resuscitation. After adjusting for age, sex, and BMI, the risk of death increased with the initiation of MT, and MT was associated with decreased 28-day ICU-free survival. Death was predicted by the severity of illness as determined by the APACHE II score, baseline hematocrit, admission respiratory rate, and BMI. Prospective studies of MT in medical patients with GIB may be helpful in determining risk factors for TRALI and risk factors which increase mortality. 
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